Vivo Capital’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.9M Sell
6,915,011
-384,898
-5% -$1.4M 2.41% 17
2026
Q2
$28.5M Sell
7,299,909
-4,120,091
-36% -$15.3M 2.6% 16
2026
Q1
$43.7M Hold
11,420,000
– – 3.64% 8
2025
Q4
$42.7M Hold
11,420,000
– – 2.76% 11
2025
Q3
$23M Buy
+11,420,000
New +$25.8M 1.85% 18

Other funds holding SABS

Vivo Capital's SABS Position: Q3 2026 in Review

Vivo Capital reduced its SAB Biotherapeutics (SABS) stake by 5.3% in Q3 2026, selling an estimated $1.4M and leaving 6,915,011 shares worth $21.9M. The position accounts for 2.41% of the portfolio, ranked #17.

Vivo Capital first reported a position in SABS in Q3 2025 and has held it in 5 quarters since. The position peaked at $43.7M in Q1 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Vivo Capital held 6,915,011 shares of SAB Biotherapeutics worth $21.9M as of Q3 2026.
  • Vivo Capital sold 384,898 SAB Biotherapeutics shares in Q3 2026, an estimated $1.4M.
  • SAB Biotherapeutics made up 2.41% of Vivo Capital's portfolio in Q3 2026, its #17 holding.
  • Vivo Capital first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 5 quarters since.
  • Vivo Capital's SAB Biotherapeutics position peaked at $43.7M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.